Endo International Plc
(NASDAQ : ENDP)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Pharmaceuticals Other
symbolcompany%chnglast%shortavg$volume
HZNPHorizon Therapeutics Plc 2.40%70.555.6%$182.80m
CTLTCatalent, Inc. 2.88%97.382.1%$122.62m
VRXValeant Pharmaceuticals International, Inc. 1.93%19.5414.1%$114.98m
BHCBausch Health Cos., Inc. 1.93%19.540.0%$82.27m
JAZZJazz Pharmaceuticals Plc 1.02%143.282.4%$79.60m
GWPHGW Pharmaceuticals Plc 1.65%129.716.1%$68.89m
PRGOPerrigo Co. Plc 0.21%48.036.8%$56.45m
UTHRUnited Therapeutics Corp. 0.35%135.5414.1%$55.32m
SAGESAGE Therapeutics, Inc. -8.62%75.578.6%$53.25m
ARGXargenx SE 6.07%281.590.0%$40.59m
SAVACassava Sciences, Inc. 0.78%7.760.0%$38.85m
ICLRICON plc 1.54%191.144.2%$36.74m
AMRNAmarin Corp. Plc 0.00%4.601.5%$36.00m
BLRXBioLineRx Ltd. 3.11%2.321.8%$35.68m
ICPTIntercept Pharmaceuticals, Inc. -0.32%37.2716.8%$32.30m

Company Profile

Endo International Plc operates as a pharmaceutical company. It focuses on developing, manufacturing, and distributing of branded and generic pharmaceutical products. The firm operates through the following segments: U.S. Branded-Specialty & Established Pharmaceuticals, U.S. Branded-Sterile Injectables, U.S. Generic Pharmaceuticals and International Pharmaceuticals. The U.S. Branded-Specialty & Established Pharmaceuticals segment offers prescription products to treat and manage conditions in urology, urologic oncology, endocrinology, pain and orthopedics. The U.S. Branded-Sterile Injectables segment consists primarily of branded sterile injectable products such as VASOSTRICT, ADRENALIN and APLISOL, among others, and certain generic sterile injectable products, including ertapenem for injection and ephedrine sulfate injection, among others. The U.S. Generic Pharmaceuticals segment consists of a differentiated product portfolio including solid oral extended-release, solid oral immediate-release, liquids, semi-solids, patches, powders, ophthalmics and sprays and includes products in the pain management, urology, central nervous system disorders, immunosuppression, oncology, women's health and cardiovascular disease markets, among others. The International Pharmaceuticals segment includes a variety of pharmaceutical products for the Canadian, Latin American, South African, and world markets. The company was founded in 1997 and is headquartered Dublin, Ireland.